Cognition Therapeutics Inc (NASDAQ: CGTX) on Monday, soared 6.95% from the previous trading day, before settling in for the closing price of $0.67. Within the past 52 weeks, CGTX’s price has moved between $0.22 and $1.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -16.44% over the last five years. The company achieved an average annual earnings per share of 52.62%. With a float of $49.82 million, this company’s outstanding shares have now reached $61.97 million.
The firm has a total of 28 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cognition Therapeutics Inc (CGTX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cognition Therapeutics Inc is 19.63%, while institutional ownership is 9.08%. The most recent insider transaction that took place on Jan 31 ’25, was worth 30,001. In this transaction CEO & President of this company bought 38,851 shares at a rate of $0.77, taking the stock ownership to the 38,851 shares.
Cognition Therapeutics Inc (CGTX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 52.62% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 32.88% during the next five years compared to -16.44% drop over the previous five years of trading.
Cognition Therapeutics Inc (NASDAQ: CGTX) Trading Performance Indicators
Cognition Therapeutics Inc (CGTX) is currently performing well based on its current performance indicators. A quick ratio of 2.09 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.73, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.28 in one year’s time.
Technical Analysis of Cognition Therapeutics Inc (CGTX)
Analysing the last 5-days average volume posted by the [Cognition Therapeutics Inc, CGTX], we can find that recorded value of 3.72 million was lower than the volume posted last year of 3.98 million. As of the previous 9 days, the stock’s Stochastic %D was 30.79%.
During the past 100 days, Cognition Therapeutics Inc’s (CGTX) raw stochastic average was set at 60.11%, which indicates a significant increase from 50.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0881 in the past 14 days, which was higher than the 0.0500 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4538, while its 200-day Moving Average is $0.4936.
